文献速递淋巴瘤

ACOX1介导的过氧化物酶体脂肪酸氧化参与慢性淋巴细胞白血病的代谢重编程与存活

ACOX1-mediated peroxisomal fatty acid oxidation contributes to metabolic reprogramming and survival in chronic lymphocytic leukemia.
PubMed 文献 · Leukemia · 2023-12-06

该研究分析慢性淋巴细胞白血病(CLL)B淋巴细胞的代谢特征,发现其线粒体氧化磷酸化活性高、糖酵解率低,并存在依赖过氧化物酶体脂肪酸β氧化(pFAO)的代谢重编程。下调ACOX1可改变CLL细胞代谢表型,完全阻断ACOX1导致脂滴积累和CLL细胞 caspase 依赖性死亡;ACOX1抑制不影响非肿瘤血细胞,且与BTK抑制剂联合具有协同杀伤效应。

要点

  • CLL B淋巴细胞表现为线粒体氧化磷酸化活性高、糖酵解率低,并依赖过氧化物酶体脂肪酸β氧化。
  • ACOX1在CLL细胞中过表达,下调ACOX1足以使CLL细胞代谢从脂质转向碳源和氨基酸表型。
  • 完全阻断ACOX1导致脂滴积累和CLL细胞caspase依赖性死亡,ACOX1与BTK抑制剂联合具有协同杀伤效应。

核心结论

  • CLL细胞存在以ACOX1介导的过氧化物酶体脂肪酸β氧化为关键特征的代谢重编程,完全阻断ACOX1可致CLL细胞死亡,ACOX1抑制与BTK抑制剂联合具有协同杀伤效应。

研究设计与样本

  • 研究检测慢性淋巴细胞白血病(CLL)患者肿瘤B淋巴细胞的特定代谢特征,并开展ACOX1下调与抑制的相关实验。

主要发现

  • CLL B淋巴细胞表现为线粒体氧化磷酸化活性高、糖酵解率低,并出现C2至C6肉碱终产物,提示过氧化物酶体脂肪酸β氧化(pFAO)发挥重要作用。
  • ACOX1(一种在CLL细胞中过表达的pFAO限速酶)下调足以使CLL细胞代谢从脂质转向碳源和氨基酸表型。
  • 完全阻断ACOX1导致CLL细胞脂滴积累和caspase依赖性死亡,包括来自细胞遗传学和临床预后因素不良个体的CLL细胞。
  • ACOX1抑制不影响CLL患者的非肿瘤血细胞,但导致循环中BCR刺激的CLL B淋巴细胞及接受促存活基质信号的CLL B细胞死亡。
  • ACOX1抑制剂与BTK抑制剂联合具有协同杀伤效应。

临床怎么用

  • 原文结论指出,结果突显了CLL中一个较少被研究但至关重要的代谢通路,并为开发基于代谢的新治疗选择铺平道路。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic lymphocytic leukemia (CLL) is still an incurable disease, with many patients developing resistance to conventional and targeted therapies. To better understand the physiology of CLL and facilitate the development of innovative treatment options, we examined specific metabolic features in the tumor CLL B-lymphocytes. We observed metabolic reprogramming, characterized by a high level of mitochondrial oxidative phosphorylation activity, a low glycolytic rate, and the presence of C2- to C6-carnitine end-products revealing an unexpected, essential role for peroxisomal fatty acid beta-oxidation (pFAO). Accordingly, downmodulation of ACOX1 (a rate-limiting pFAO enzyme overexpressed in CLL cells) was enough to shift the CLL cells' metabolism from lipids to a carbon- and amino-acid-based phenotype. Complete blockade of ACOX1 resulted in lipid droplet accumulation and caspase-dependent death in CLL cells, including those from individuals with poor cytogenetic and clinical prognostic factors. In a therapeutic translational approach, ACOX1 inhibition spared non-tumor blood cells from CLL patients but led to the death of circulating, BCR-stimulated CLL B-lymphocytes and CLL B-cells receiving pro-survival stromal signals. Furthermore, a combination of ACOX1 and BTK inhibitors had a synergistic killing effect. Overall, our results highlight a less-studied but essential metabolic pathway in CLL and pave the way towards the development of new, metabolism-based treatment options.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Tannoury M, Ayoub M, Dehgane L, et al. ACOX1-mediated peroxisomal fatty acid oxidation contributes to metabolic reprogramming and survival in chronic lymphocytic leukemia. Leukemia. 2023. PMID: 38057495. doi:10.1038/s41375-023-02103-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。